Brought to you by 
Syros Pharmaceuticals raises $30mm through Series A round
Apr 2013
Executive Summary
Syros Pharmaceuticals Inc., a newly established company that aims to develop therapies targeting the switches that control genes, has launched and raised $30mm through its Series A round. Company co-founders Arch Venture Partners and Flagship Ventures led, and were joined by WuXi PharmaTech Corporate Venture Fund and other private investors.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Syros Pharmaceuticals raises $30mm through Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice